EMA Authorised: Suliqua (insulin glargine;lixisenatide) — Sanofi Winthrop Industrie

View source ↗

Summary

Suliqua (insulin glargine and lixisenatide) has been authorised for type 2 diabetes mellitus in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Suliqua (insulin glargine; lixisenatide)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Sanofi Winthrop Industrie. Decision date: 01/07/2026